Cryptococcus neoformans Hsp70 antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Cryptococcus neoformans Hsp70 antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine infectious disease Cryptococcosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Companion Animal disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P034-Tg001-Ag01	Recombinant Cryptococcus neoformans Hsp70 protein	$3090.00
GMP-VT-P034-Tg001-Ab01	Anti-Cryptococcus neoformans Hsp70 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P034-Tg001-Ab02	Anti-Cryptococcus neoformans Hsp70 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P034-Tg001-Ab03	Anti-Cryptococcus neoformans Hsp70 human monoclonal antibody (mAb)	$3090.00
GMP-VT-P034-Tg001-Ab04	Anti-Cryptococcus neoformans Hsp70 human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P034-Tg001-Ag01
Product Name	Recombinant Cryptococcus neoformans Hsp70 protein
Pathogen	Cryptococcus neoformans
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Cryptococcus neoformans Hsp70 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Cryptococcus neoformans level test of animal Cat/Feline, Dog/Canine infectious disease with Cryptococcosis.
Tag	His
Product description	Recombinant Cryptococcus neoformans Hsp70 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P034-Tg001-Ab01,GMP-VT-P034-Tg001-Ab02
Pathogen	Cryptococcus neoformans
Product Name	Anti-Cryptococcus neoformans Hsp70 mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Cryptococcus neoformans Hsp70 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Cryptococcus neoformans antibodies in Cryptococcus neoformans level test of animal Cat/Feline, Dog/Canine infectious disease with Cryptococcosis.
Product description	Anti-Cryptococcus neoformans Hsp70 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Cryptococcus neoformans antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P034-Tg001-Ab03,GMP-VT-P034-Tg001-Ab04
Pathogen	Cryptococcus neoformans
Product Name	Anti-Cryptococcus neoformans Hsp70 human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Cryptococcus neoformans Hsp70 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Cryptococcus neoformans antibodies in Cryptococcus neoformans level test of animal Cat/Feline, Dog/Canine infectious disease with Cryptococcosis.
Product description	Anti-Cryptococcus neoformans Hsp70 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Cryptococcus neoformans is a medically significant pathogen that belongs to the fungal kingdom. This eukaryotic organism is a basidiomycetous yeast species, and it is well-known for its ability to cause disease in humans and other animals. In this article, we will explore the characteristics of Cryptococcus neoformans, including its structure, virulence factors, host range, pathogenesis, and diagnostic methods.

Structure of Cryptococcus neoformans

Cryptococcus neoformans is a spherical unicellular organism with a diameter typically ranging from 4-7 µm. It has a complex cell wall structure consisting of an outermost capsule, which is composed of glucuronoxylomannan (GXM), and an inner cell wall layer containing chitin and β-glucans. Beneath the cell wall, the plasma membrane surrounds the cytoplasmic contents of the cell.

Virulence factors of Cryptococcus neoformans

The pathogenesis of Cryptococcus neoformans is primarily attributed to the presence of virulence factors such as its polysaccharide capsule, which is encoded by the CAP59 gene. The capsule is an important virulence factor as it protects the yeast cell from phagocytosis by host immune cells, allowing the pathogen to evade host defenses and proliferate within the host. Another key component of Cryptococcus neoformans virulence is melanin, which is produced via the L-DOPA dioxygenase enzyme (Lac1). Melanin plays various roles in the survival of the pathogen, including protection against oxidative stress, UV radiation, and antifungal agents.

Host range and diseases caused by Cryptococcus neoformans

Cryptococcus neoformans has a broad host range, including birds, rodents, and mammals. In humans, it can cause several diseases such as cryptococcal meningitis, pneumonia, and skin infections. The pathogen primarily infects immunocompromised individuals, including those with HIV/AIDS, organ transplant recipients, and those on long-term corticosteroid therapy. The symptoms of cryptococcosis typically vary depending on the site of infection, but common symptoms include fever, headache, cough, and respiratory distress.

Pathogenesis of Cryptococcus neoformans

The pathogenesis of Cryptococcus neoformans involves several steps, including inhalation of fungal spores from the environment, alveolar macrophage phagocytosis, and dissemination to other organs through the bloodstream. Once inside the host, Cryptococcus neoformans evades host immune responses through its capsule-mediated virulence and melanin production. It can also modulate host immune responses by targeting host signaling pathways and immune cells.

Diagnostic methods for Cryptococcus neoformans

The diagnosis of Cryptococcus neoformans infections is based on clinical symptoms, imaging studies, and laboratory testing. Laboratory testing includes direct microscopy and culture of cerebrospinal fluid, blood, or other bodily fluids, antigen testing, and nucleic acid amplification tests. These methods typically target the capsular polysaccharides (detected via antigen testing), 18S rRNA gene, and LAC1 gene. Recently, next-generation sequencing techniques such as whole-genome sequencing (WGS) have been used to identify Cryptococcus neoformans strains and study their genomic diversity.

Conclusion

Cryptococcus neoformans is a medically significant fungal pathogen that causes severe diseases in humans and other animals. Its complex cell wall structure, virulence factors such as the polysaccharide capsule and melanin production, broad host range, and ability to modulate host immune responses make it a formidable pathogen. While diagnostic methods have improved in recent years, more research is needed to better understand the genetic and molecular mechanisms underlying Cryptococcus neoformans virulence and pathogenesis.

About GDU